Symbols / BIOA Stock $23.32 +2.12% BioAge Labs, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NMS
BIOA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Dr. Kristen Fortney Ph.D.
Exch · Country NMS · United States
Market Cap 1.04B
Enterprise Value 635.70M
Income -89.93M
Sales 10.32M
FCF (ttm) -58.34M
Book/sh 8.54
Cash/sh 8.62
Employees 60
Insider 10d —
IPO Sep 26, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 1.58
Forward P/E -11.32
PEG —
P/S 100.47
P/B 2.73
P/C —
EV/EBITDA -6.26
EV/Sales 61.62
Quick Ratio 24.38
Current Ratio 24.76
Debt/Eq 1.06
LT Debt/Eq —
EPS (ttm) -2.40
EPS next Y -2.06
EPS Growth —
Revenue Growth 91.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-08
ROA -17.15%
ROE -25.98%
ROIC —
Gross Margin 0.00%
Oper. Margin -9.15%
Profit Margin 0.00%
Shs Outstand 44.45M
Shs Float 33.69M
Insider Own 2.44%
Instit Own 85.53%
Short Float 4.55%
Short Ratio 4.31
Short Interest 1.79M
52W High 24.93
vs 52W High -6.48%
52W Low 4.07
vs 52W Low 473.55%
Beta —
Impl. Vol. 95.51%
Rel Volume 1.23
Avg Volume 437.06K
Volume 536.33K
Target (mean) $49.50
Tgt Median $51.00
Tgt Low $23.00
Tgt High $73.00
# Analysts 8
Recom Buy
Prev Close $22.83
Price $23.32
Change 2.12%
About

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$49.50
Mean price target
2. Current target
$23.32
Latest analyst target
3. DCF / Fair value
$-23.62
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$23.32
Low
$23.00
High
$73.00
Mean
$49.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-27 init Roth Capital — → Buy $36
2026-05-13 init BTIG — → Buy $40
2026-03-27 init Needham — → Buy $50
2026-03-10 main Citigroup Buy → Buy $52
2026-02-25 init Oppenheimer — → Outperform $60
2026-02-18 up Jefferies Hold → Buy $62
2026-01-27 init Piper Sandler — → Overweight $73
2025-12-08 up Morgan Stanley Underweight → Equal-Weight $12
2025-10-29 main Citigroup Buy → Buy $15
2025-10-22 up Citigroup Neutral → Buy $10
2025-03-24 main Citigroup Neutral → Neutral $5
2025-02-28 init William Blair — → Market Perform —
2024-12-09 down Citigroup Buy → Neutral $7
2024-12-09 down Jefferies Buy → Hold $7
News
RSS: Latest BIOA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-23 GOLDSTEIN DOV A Chief Financial Officer — 3,542 $4.38 $15,514
2026-04-01 RUBIN PAUL D Officer — 8,820 $17.81 $157,084
2026-04-01 RUBIN PAUL D Officer — 8,820 $4.11 $44,572
2026-03-02 RUBIN PAUL D Officer — 7,433 $20.30 $150,890
2026-03-02 RUBIN PAUL D Officer — 7,433 $4.11 $35,470
2026-02-27 GOLDSTEIN DOV A Chief Financial Officer — 3,542 $4.38 $15,514
2026-02-02 RUBIN PAUL D Officer — 7,433 $18.75 $139,369
2026-02-02 RUBIN PAUL D Officer — 7,433 $4.11 $35,470
2026-01-30 GOLDSTEIN DOV A Chief Financial Officer — 3,541 $4.38 $15,510
2026-01-16 GOLDSTEIN DOV A Chief Financial Officer — 3,542 $4.38 $15,514
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
8.99
0.00
0.00
0.00
Operating Revenue
8.99
0.00
0.00
0.00
Operating Expense
101.78
+30.16%
78.19
+61.56%
48.40
+21.09%
39.97
Research And Development
73.97
+25.29%
59.04
+74.22%
33.89
+11.02%
30.52
Selling General And Administration
27.81
+45.16%
19.16
+32.00%
14.51
+53.64%
9.45
General And Administrative Expense
27.81
+45.16%
19.16
+32.00%
14.51
+53.64%
9.45
Other Gand A
27.81
+45.16%
19.16
+32.00%
14.51
+53.64%
9.45
Total Expenses
101.78
+30.16%
78.19
+61.56%
48.40
+21.09%
39.97
Operating Income
-92.78
-18.65%
-78.19
-61.56%
-48.40
-21.09%
-39.97
Total Operating Income As Reported
-92.78
-18.65%
-78.19
-61.56%
-48.40
-21.09%
-39.97
EBITDA
-79.69
-16.22%
-68.58
-22.68%
-55.90
-42.05%
-39.35
Normalized EBITDA
-79.48
-16.20%
-68.40
-49.32%
-45.81
-16.34%
-39.38
Reconciled Depreciation
0.21
+27.54%
0.17
+3.09%
0.16
+25.58%
0.13
EBIT
-79.91
-16.24%
-68.74
-22.62%
-56.06
-41.99%
-39.48
Total Unusual Items
-0.21
-20.90%
-0.18
+98.25%
-10.09
-43973.91%
0.02
Total Unusual Items Excluding Goodwill
-0.21
-20.90%
-0.18
+98.25%
-10.09
-43973.91%
0.02
Special Income Charges
0.00
+100.00%
-0.25
0.00
—
Other Special Charges
—
0.25
—
—
Net Income
-80.61
-13.35%
-71.11
-11.36%
-63.85
-60.75%
-39.72
Pretax Income
-80.61
-13.35%
-71.11
-11.36%
-63.85
-60.75%
-39.72
Net Non Operating Interest Income Expense
12.39
+70.60%
7.26
+235.41%
-5.36
-2494.20%
0.22
Interest Expense Non Operating
0.70
-70.55%
2.37
-69.63%
7.79
+3134.02%
0.24
Net Interest Income
12.39
+70.60%
7.26
+235.41%
-5.36
-2494.20%
0.22
Interest Expense
0.70
-70.55%
2.37
-69.63%
7.79
+3134.02%
0.24
Interest Income Non Operating
13.09
+35.90%
9.63
+296.09%
2.43
+422.80%
0.47
Interest Income
13.09
+35.90%
9.63
+296.09%
2.43
+422.80%
0.47
Other Income Expense
-0.21
-20.90%
-0.18
+98.25%
-10.09
-43973.91%
0.02
Gain On Sale Of Security
-0.21
-393.15%
0.07
+100.72%
-10.09
-43973.91%
0.02
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-80.61
-13.35%
-71.11
-11.36%
-63.85
-60.75%
-39.72
Net Income From Continuing Operation Net Minority Interest
-80.61
-13.35%
-71.11
-11.36%
-63.85
-60.75%
-39.72
Net Income From Continuing And Discontinued Operation
-80.61
-13.35%
-71.11
-11.36%
-63.85
-60.75%
-39.72
Net Income Continuous Operations
-80.61
-13.35%
-71.11
-11.36%
-63.85
-60.75%
-39.72
Normalized Income
-80.39
-13.34%
-70.93
-31.93%
-53.76
-35.27%
-39.74
Net Income Common Stockholders
-80.61
-13.35%
-71.11
-11.36%
-63.85
-60.75%
-39.72
Diluted EPS
-2.24
+66.21%
-6.63
-108.91%
-3.17
+86.64%
-23.76
Basic EPS
-2.24
+66.21%
-6.63
-108.91%
-3.17
+86.64%
-23.76
Basic Average Shares
35.93
+234.99%
10.73
-46.69%
20.12
+1103.51%
1.67
Diluted Average Shares
35.93
+234.99%
10.73
-46.69%
20.12
+1103.51%
1.67
Diluted NI Availto Com Stockholders
-80.61
-13.35%
-71.11
-11.36%
-63.85
-60.75%
-39.72
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
294.89
-17.68%
358.23
+1281.86%
25.92
-8.81%
28.43
Current Assets
286.79
-19.69%
357.10
+1311.14%
25.31
-9.72%
28.03
Cash Cash Equivalents And Short Term Investments
281.10
-20.67%
354.35
+1537.17%
21.64
-21.70%
27.64
Cash And Cash Equivalents
188.89
-46.69%
354.35
+1537.17%
21.64
-21.70%
27.64
Other Short Term Investments
92.21
0.00
—
—
Receivables
0.77
0.00
—
—
Accounts Receivable
0.77
0.00
—
—
Restricted Cash
—
0.00
-100.00%
3.31
0.00
Other Current Assets
4.93
+78.87%
2.75
+689.11%
0.35
-9.59%
0.39
Total Non Current Assets
8.10
+615.83%
1.13
+83.01%
0.62
+54.89%
0.40
Net PPE
3.75
+373.83%
0.79
+52.70%
0.52
+38.50%
0.37
Gross PPE
4.23
+264.03%
1.16
+24.01%
0.94
+49.44%
0.63
Accumulated Depreciation
-0.48
-29.92%
-0.37
+11.46%
-0.42
-65.61%
-0.25
Properties
0.00
0.00
—
—
Machinery Furniture Equipment
0.24
+104.27%
0.12
-68.88%
0.38
+23.28%
0.30
Construction In Progress
0.02
-87.50%
0.18
0.00
—
Other Properties
3.81
+338.20%
0.87
+54.90%
0.56
+74.22%
0.32
Leases
0.16
0.00
—
—
Investments And Advances
4.13
+4032.00%
0.10
+0.00%
0.10
0.00
Other Investments
0.10
+0.00%
0.10
+0.00%
0.10
0.00
Other Non Current Assets
0.22
-10.00%
0.24
—
0.03
Total Liabilities Net Minority Interest
22.84
-34.95%
35.11
-82.39%
199.32
+41.37%
140.99
Current Liabilities
20.14
-27.50%
27.77
-52.25%
58.17
+892.46%
5.86
Payables And Accrued Expenses
10.63
-20.26%
13.33
+58.41%
8.41
+49.71%
5.62
Payables
2.67
+33.97%
2.00
+6.97%
1.87
-17.47%
2.26
Accounts Payable
2.67
+33.97%
2.00
+6.97%
1.87
-17.47%
2.26
Current Accrued Expenses
7.96
-29.81%
11.33
+73.06%
6.55
+94.91%
3.36
Current Debt And Capital Lease Obligation
3.23
-47.92%
6.20
-86.23%
45.05
+20756.94%
0.22
Current Debt
2.65
-55.87%
6.00
-86.62%
44.86
+26760.48%
0.17
Other Current Borrowings
2.65
-55.87%
6.00
-86.62%
44.86
+26760.48%
0.17
Current Capital Lease Obligation
0.58
+188.12%
0.20
+4.12%
0.19
+295.92%
0.05
Current Deferred Liabilities
5.75
-26.48%
7.83
+136.22%
3.31
0.00
Current Deferred Revenue
5.75
-26.48%
7.83
+136.22%
3.31
0.00
Other Current Liabilities
0.53
+25.90%
0.42
-69.98%
1.39
+5687.50%
0.02
Total Non Current Liabilities Net Minority Interest
2.70
-63.18%
7.33
-94.81%
141.15
+4.46%
135.13
Long Term Debt And Capital Lease Obligation
2.33
-6.87%
2.50
-69.49%
8.20
+264.17%
2.25
Long Term Debt
—
2.50
-69.49%
8.20
+264.17%
2.25
Long Term Capital Lease Obligation
2.33
0.00
—
—
Non Current Deferred Liabilities
0.00
-100.00%
4.67
0.00
—
Non Current Deferred Revenue
0.00
-100.00%
4.67
0.00
—
Preferred Securities Outside Stock Equity
—
0.00
-100.00%
132.72
+0.00%
132.72
Stockholders Equity
272.05
-15.81%
323.13
+286.35%
-173.40
-54.05%
-112.56
Common Stock Equity
272.05
-15.81%
323.13
+286.35%
-173.40
-54.05%
-112.56
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
0.00
0.00
—
—
Share Issued
37.39
+4.29%
35.85
+4.93%
34.17
+0.00%
34.17
Ordinary Shares Number
37.39
+4.29%
35.85
+4.93%
34.17
+0.00%
34.17
Additional Paid In Capital
605.19
+5.12%
575.69
+6970.66%
8.14
+58.96%
5.12
Retained Earnings
-333.42
-31.88%
-252.81
-39.13%
-181.70
-54.18%
-117.85
Gains Losses Not Affecting Retained Earnings
0.28
+13.47%
0.24
+49.39%
0.16
-1.80%
0.17
Other Equity Adjustments
0.28
+13.47%
0.24
+49.39%
0.16
-1.80%
0.17
Total Equity Gross Minority Interest
272.05
-15.81%
323.13
+286.35%
-173.40
-54.05%
-112.56
Total Capitalization
272.05
-16.45%
325.63
+297.12%
-165.19
-49.76%
-110.31
Working Capital
266.65
-19.03%
329.33
+1102.15%
-32.86
-248.23%
22.17
Invested Capital
274.70
-17.17%
331.63
+375.58%
-120.34
-9.26%
-110.14
Total Debt
5.56
-36.12%
8.70
-83.66%
53.25
+2057.70%
2.47
Net Debt
—
—
31.41
—
Capital Lease Obligations
2.91
+1341.58%
0.20
+4.12%
0.19
+295.92%
0.05
Net Tangible Assets
272.05
-15.81%
323.13
+286.35%
-173.40
-54.05%
-112.56
Tangible Book Value
272.05
-15.81%
323.13
+286.35%
-173.40
-54.05%
-112.56
Available For Sale Securities
4.03
—
—
—
Derivative Product Liabilities
0.37
+137.18%
0.16
-31.88%
0.23
+49.67%
0.15
Investmentin Financial Assets
4.03
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-81.63
-58.43%
-51.52
-37.90%
-37.36
-3.26%
-36.18
Cash Flow From Continuing Operating Activities
-81.63
-58.43%
-51.52
-37.90%
-37.36
-3.26%
-36.18
Net Income From Continuing Operations
-80.61
-13.35%
-71.11
-11.36%
-63.85
-60.75%
-39.72
Depreciation Amortization Depletion
0.21
+27.54%
0.17
+3.09%
0.16
+25.58%
0.13
Depreciation
0.21
+27.54%
0.17
+3.09%
0.16
+25.58%
0.13
Depreciation And Amortization
0.21
+27.54%
0.17
+3.09%
0.16
+25.58%
0.13
Other Non Cash Items
-1.33
-229.24%
1.03
-84.14%
6.51
+6413.00%
0.10
Stock Based Compensation
11.69
+67.52%
6.98
+131.40%
3.02
+18.74%
2.54
Operating Gains Losses
0.24
+2.16%
0.23
-97.70%
10.09
+43973.91%
-0.02
Gain Loss On Investment Securities
0.21
+393.15%
-0.07
-100.72%
10.09
+43973.91%
-0.02
Gain Loss On Sale Of PPE
0.02
-58.18%
0.06
0.00
—
Change In Working Capital
-11.83
-205.83%
11.18
+66.56%
6.71
+744.03%
0.80
Change In Receivables
-0.77
0.00
—
—
Changes In Account Receivables
-0.77
0.00
—
—
Change In Prepaid Assets
-1.71
+28.77%
-2.40
-6600.00%
0.04
+223.33%
-0.03
Change In Payables And Accrued Expense
-2.62
-156.62%
4.63
+38.95%
3.33
+605.07%
0.47
Change In Accrued Expense
-3.41
-173.73%
4.63
+24.14%
3.73
+815.55%
-0.52
Change In Payable
0.79
+13033.33%
0.01
+101.53%
-0.39
-139.54%
0.99
Change In Account Payable
0.79
+13033.33%
0.01
+101.53%
-0.39
-139.54%
0.99
Change In Other Working Capital
-6.75
-173.43%
9.19
+177.30%
3.31
—
Change In Other Current Assets
0.02
+110.00%
-0.24
-1060.00%
0.03
-92.90%
0.35
Investing Cash Flow
-95.22
-25915.30%
-0.37
-37.59%
-0.27
-158.25%
-0.10
Cash Flow From Continuing Investing Activities
-95.22
-25915.30%
-0.37
-37.59%
-0.27
-158.25%
-0.10
Net PPE Purchase And Sale
-0.72
-96.45%
-0.37
-120.48%
-0.17
-61.17%
-0.10
Purchase Of PPE
-0.72
-96.45%
-0.37
-120.48%
-0.17
-61.17%
-0.10
Capital Expenditure
-0.72
-96.45%
-0.37
-120.48%
-0.17
-61.17%
-0.10
Net Investment Purchase And Sale
-94.50
0.00
+100.00%
-0.10
0.00
Purchase Of Investment
-154.75
0.00
+100.00%
-0.10
0.00
Sale Of Investment
60.25
0.00
—
—
Financing Cash Flow
11.47
-96.99%
381.20
+990.98%
34.94
+1298.20%
2.50
Cash Flow From Continuing Financing Activities
11.47
-96.99%
381.20
+990.98%
34.94
+1298.20%
2.50
Net Issuance Payments Of Debt
-6.00
+0.00%
-6.00
-117.14%
35.00
+1300.00%
2.50
Issuance Of Debt
—
0.00
-100.00%
36.00
+1340.00%
2.50
Repayment Of Debt
-6.00
+0.00%
-6.00
-500.00%
-1.00
0.00
Long Term Debt Issuance
—
0.00
-100.00%
12.50
+400.00%
2.50
Long Term Debt Payments
-6.00
+0.00%
-6.00
-500.00%
-1.00
0.00
Net Long Term Debt Issuance
-6.00
+0.00%
-6.00
-152.17%
11.50
+360.00%
2.50
Short Term Debt Issuance
—
0.00
-100.00%
23.50
0.00
Net Short Term Debt Issuance
—
0.00
-100.00%
23.50
0.00
Net Common Stock Issuance
17.16
-92.26%
221.62
0.00
—
Proceeds From Stock Option Exercised
0.71
+12.62%
0.63
+15750.00%
0.00
-90.91%
0.04
Net Other Financing Charges
-0.40
+92.09%
-5.05
-7922.22%
-0.06
-40.00%
-0.04
Changes In Cash
-165.37
-150.22%
329.31
+12355.71%
-2.69
+92.05%
-33.78
Effect Of Exchange Rate Changes
-0.09
-207.41%
0.08
0.00
-100.00%
0.25
Beginning Cash Position
354.35
+1319.84%
24.96
-9.72%
27.64
-54.82%
61.18
End Cash Position
188.89
-46.69%
354.35
+1319.84%
24.96
-9.72%
27.64
Free Cash Flow
-82.35
-58.70%
-51.89
-38.26%
-37.53
-3.43%
-36.28
Interest Paid Supplemental Data
0.61
-56.97%
1.42
+22.94%
1.16
+795.35%
0.13
Common Stock Issuance
17.16
-92.26%
221.62
0.00
—
Issuance Of Capital Stock
17.16
-95.62%
391.62
0.00
—
Net Preferred Stock Issuance
0.00
-100.00%
170.00
0.00
—
Preferred Stock Issuance
0.00
-100.00%
170.00
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category